Physician profile
Frank T Armstrong
NPI 1952390148
$13,543.81
in general payments reported to CMS, 2019-2025
44 companies · $2,543 in 2025
The $2,543 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,219 · 2020: $865 · 2021: $801 · 2022: $1,569 · 2023: $1,822 · 2024: $1,724 · 2025: $2,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,850 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,850.08 |
| Education | $239.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,571.95 | 2019-2023 | Xeomin |
| Biofrontera INC. | $1,160.04 | 2019-2020 | |
| Abbvie INC. | $987.20 | 2019-2025 | Skyrizi |
| Hill Dermaceuticals, INC. | $861.20 | 2020-2025 | Tolak |
| Lilly USA, LLC | $798.54 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $789.52 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $701.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $667.92 | 2019-2025 | Ilumya |
| Genzyme Corporation | $660.40 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $477.68 | 2019-2025 | Siliq, Cabtreo, Targretin |
| Ucb, INC. | $386.51 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $322.80 | 2023-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $310.62 | 2019-2025 | |
| Janssen Biotech, INC. | $292.52 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $274.18 | 2019-2025 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.